Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | ITGAL | P20701 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2079090 | 1.00 | MAPT (0.55) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL481451 | 0.87 | MAPT (0.65) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL29419102 | 0.87 | MAPT (0.65) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL165227 | 0.87 | MAPT (0.65) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL2082270 | 0.86 | MAPT (0.55) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL2082273 | 0.86 | MAPT (0.55) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL6822024 | 0.86 | MAPT (0.63) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL27093058 | 0.86 | MAPT (0.63) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL11459860 | 0.86 | MAPT (0.63) | MAPTALDH1A1L3MBTL1KDM4EGAA | |
| SCHEMBL11454521 | 0.83 | TDP1 (0.60) | MAPTALDH1A1L3MBTL1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897601-B2 | Cannabinoid receptor modulators | INTERVET, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| EP-1973877-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084450-A2 | CANNIBINOID RECEPTOR MODULATORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-6458806-B1 | ANTIINFLAMMATORY AND -ARTHRITIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS; TRANSPLANT REJECTION; INFLAMMATORY BOWEL DISEASES, CROHN'S DISEASE, ANTIALLERGENS; IMMUNE, SKIN GASTROINTESTINAL AND RESPIRATORY SYSTEM DIORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | CCR2, CCR1, MSR1 | MAPT 4720/4885ALDH1A1 1447/4885L3MBTL1 1385/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | MAPT 1582/4885ALDH1A1 1999/4885L3MBTL1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.